Last reviewed · How we verify
MR Vaccine SII
At a glance
| Generic name | MR Vaccine SII |
|---|---|
| Sponsor | PT Bio Farma |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine (PHASE3)
- Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MR Vaccine SII CI brief — competitive landscape report
- MR Vaccine SII updates RSS · CI watch RSS
- PT Bio Farma portfolio CI